The National Agency for Food and Drug Administration and Control (NAFDAC) is alerting healthcare providers and the public about the circulation of counterfeit Dermazin (1% Silver Sulphadiazine) Cream.
NAFDAC received a complaint from the legitimate Marketing Authorization Holder, Taylek Drugs Company Limited, concerning the sale of this counterfeit product. The packaging of the falsified Dermazin Cream falsely claims that it is produced by Taylek Drugs Company Limited.
Risk Statement
The illegal marketing of medicinal products and counterfeit medicines is a significant health risk as it fails to ensure the safety, quality, and efficacy of these items, violating regulatory standards.
Product details
The details of the counterfeit products are as follows:
Product Details | Original | Counterfeit |
Product Name | Dermazin (1% Silver Sulphadiazine) Cream | Dermazin (1% Silver Sulphadiazine) Cream |
Stated Manufacturer | Salutas Pharma GmbH 39171 Osterweddingen, Germany | Salutas Pharma GmbH 39171 Osterweddingen, Germany |
Batch Number | PF6565 | MV5093 |
Manufacturing Date | 11/2024 | 05/2024 |
Expiry Date | 10/2027 | 05/2027 |
Product Photo
Original
Counterfeit
All NAFDAC zonal directors and state coordinators have been instructed to conduct surveillance and remove the counterfeited product if found within their zones and states.
Distributors, retailers, healthcare professionals, and caregivers are hereby advised to exercise caution and vigilance within the supply chain to avoid the distribution, sale, and use of counterfeit products. All medical products must be purchased from authorized or licensed suppliers. The products’ authenticity and physical condition should be carefully checked.
Healthcare professionals and consumers are advised to report any suspicion of the sale of substandard and falsified medicines or medical devices to the nearest NAFDAC office, call NAFDAC on 0800-162-3322, or via email: sf.alert@nafdac.gov.ng
Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of medicinal products or devices to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng , or via the Med- safety application available for download on Android and IOS stores, or via e-mail on pharmacovigilance@nafdac.gov.ng
For complaints, you can call the Reforms Unit on the following lines: 09097630506, 09097630507, or email: reforms@nafdac.gov.ng
Furthermore, note that this notice will be uploaded to the WHO Global Surveillance and Monitoring System (GSMS).
NAFDAC……….Customer-focused, Agency-minded!!!
